{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T10:57:19Z","timestamp":1791197839673,"version":"4.1.0"},"reference-count":84,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jaci.2026.07.007","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T15:51:39Z","timestamp":1784908299000},"page":"1010-1017","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["International perspective on obtaining disease modification with food allergy therapies"],"prefix":"10.1016","volume":"158","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6240-7437","authenticated-orcid":false,"given":"Aikaterini","family":"Anagnostou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillipe","family":"B\u00e9gin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Eiwegger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Greenhawt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas P.","family":"Mack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alkis","family":"Togias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2026.07.007_bib1","doi-asserted-by":"crossref","DOI":"10.1001\/jamapediatrics.2025.6105","article-title":"Risk factors for the development of food allergy in infants and children: a systematic review and meta-analysis","author":"Islam","year":"2026","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.jaci.2026.07.007_bib2","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s40521-022-00306-5","article-title":"The economic burden of food allergy: what we know and what we need to learn","volume":"9","author":"Fong","year":"2022","journal-title":"Curr Treat Options Allergy"},{"issue":"April","key":"10.1016\/j.jaci.2026.07.007_bib3","first-page":"1","article-title":"APPEAL-1: a multiple-country European survey assessing the psychosocial impact of peanut allergy","author":"DunnGalvin","year":"2020","journal-title":"Allergy Eur J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.07.007_bib4","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.anai.2010.07.011","article-title":"Bullying among pediatric patients with food allergy","volume":"105","author":"Lieberman","year":"2010","journal-title":"Ann Allergy, Asthma, Immunol"},{"key":"10.1016\/j.jaci.2026.07.007_bib6","series-title":"FDA approves first medication to help reduce allergic reactions to multiple foods after accidental exposure","year":"2024"},{"key":"10.1016\/j.jaci.2026.07.007_bib7","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1002\/bcp.70048","article-title":"European Medicines Agency (EMA) commentary on EMA\/CHMP guideline on allergen products development for immunotherapy and allergy diagnosis in moderate to low-sized study populations","volume":"91","author":"Bonertz","year":"2025","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jaci.2026.07.007_bib8","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1056\/NEJM199908123410702","article-title":"Long-term clinical efficacy of grass-pollen immunotherapy","volume":"341","author":"Durham","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2026.07.007_bib9","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1398-9995.2008.01875.x","article-title":"Efficacy of grass pollen sublingual immunotherapy for three consecutive seasons and after cessation of treatment: the ECRIT study","volume":"64","author":"Ott","year":"2009","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2026.07.007_bib10","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13601-015-0057-8","article-title":"Prolonged efficacy of the 300IR 5-grass pollen tablet up to 2 years after treatment cessation, as measured by a recommended daily combined score","volume":"5","author":"Didier","year":"2015","journal-title":"Clin Transl Allergy"},{"key":"10.1016\/j.jaci.2026.07.007_bib11","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.jaci.2011.12.973","article-title":"SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial","volume":"129","author":"Durham","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.07.007_bib12","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jaci.2017.06.014","article-title":"Results from the 5-year SQ grass sublingual immunotherapy tablet asthma prevention (GAP) trial in children with grass pollen allergy","volume":"141","author":"Valovirta","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.07.007_bib13","doi-asserted-by":"crossref","first-page":"4103","DOI":"10.1016\/j.jaip.2021.06.060","article-title":"Disease-modifying effect of Japanese cedar pollen sublingual immunotherapy tablets","volume":"9","author":"Yonekura","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2026.07.007_bib14","doi-asserted-by":"crossref","first-page":"141","DOI":"10.18176\/jiaci.0350","article-title":"Rapid desensitization to adalimumab is associated with decreased basophil sensitivity","volume":"29","author":"Th\u00e9venot","year":"2019","journal-title":"J Investig Allergol Clin Immunol"},{"key":"10.1016\/j.jaci.2026.07.007_bib15","doi-asserted-by":"crossref","first-page":"D746","DOI":"10.2741\/A318","article-title":"IgE-mediated desensitization in human basophils and mast cells","volume":"3","author":"MacGlashan","year":"1998","journal-title":"Front Biosci"},{"key":"10.1016\/j.jaci.2026.07.007_bib16","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1007\/s10875-011-9605-8","article-title":"In vitro desensitization of human skin mast cells","volume":"32","author":"Zhao","year":"2012","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.jaci.2026.07.007_bib17","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.jaci.2022.01.016","article-title":"Diverse immune mechanisms of allergen immunotherapy for allergic rhinitis with and without asthma","volume":"149","author":"Shamji","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.07.007_bib18","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1097\/ACI.0000000000000580","article-title":"B-cell responses in allergen immunotherapy","volume":"19","author":"Satitsuksanoa","year":"2019","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.07.007_bib19","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1016\/j.jaci.2018.10.016","article-title":"The effect of regulatory T cells on tolerance to airborne allergens and allergen immunotherapy","volume":"142","author":"Bacher","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.07.007_bib20","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1056\/NEJMoa1200435","article-title":"Oral immunotherapy for treatment of egg allergy in children","volume":"367","author":"Burks","year":"2012","journal-title":"N Engl J Med"},{"issue":"10322","key":"10.1016\/j.jaci.2026.07.007_bib21","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0140-6736(21)02390-4","article-title":"Efficacy and safety of oral immunotherapy in children aged 1-3 years with peanut allergy (the Immune Tolerance Network IMPACT trial): a randomised placebo-controlled study","volume":"399","author":"Jones","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2026.07.007_bib22","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.jaip.2025.02.014","article-title":"Moving beyond desensitization to tolerance in food allergy","volume":"13","author":"Flom","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2026.07.007_bib23","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.jaip.2023.01.033","article-title":"Endpoints and outcomes after immunotherapy for food allergy: what is meaningful for patients?","volume":"11","author":"Lloyd","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2026.07.007_bib24","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2400306","article-title":"Peanut oral immunotherapy in children with high-threshold peanut allergy","volume":"4","author":"Sicherer","year":"2025","journal-title":"NEJM Evid"},{"key":"10.1016\/j.jaci.2026.07.007_bib25","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.jaci.2013.11.007","article-title":"Sustained unresponsiveness to peanut in subjects who have completed peanut oral immunotherapy","volume":"133","author":"Vickery","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.07.007_bib26","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.jaci.2018.10.028","article-title":"Predicting development of sustained unresponsiveness to milk oral immunotherapy using epitope-specific antibody binding profiles","volume":"143","author":"Su\u00e1rez-Fari\u00f1as","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.07.007_bib27","doi-asserted-by":"crossref","first-page":"174","DOI":"10.23822\/EurAnnACI.1764-1489.254","article-title":"Sustained unresponsiveness development in wheat oral immunotherapy: predictive factors and flexible regimen in the maintenance phase","volume":"55","author":"Pourvali","year":"2023","journal-title":"Eur Ann Allergy Clin Immunol"},{"issue":"10207","key":"10.1016\/j.jaci.2026.07.007_bib28","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/S0140-6736(19)31793-3","article-title":"Sustained outcomes in oral immunotherapy for peanut allergy (POISED study): a large, randomised, double-blind, placebo-controlled, phase 2 study","volume":"394","author":"Chinthrajah","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2026.07.007_bib29","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1111\/all.16493","article-title":"Oral immunotherapy in peanut-allergic adults using real-world materials","volume":"80","author":"Hunter","year":"2025","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2026.07.007_bib30","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.anai.2024.03.020","article-title":"Oral immunotherapy in food-allergic adults is safe and effective, particularly for foods other than milk","volume":"132","author":"Epstein-Rigbi","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2026.07.007_bib31","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.jaip.2023.10.047","article-title":"Long-term clinical outcome of oral immunotherapy in adults with milk, peanut, and egg allergy: a pilot study","volume":"12","author":"Thomander","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2026.07.007_bib32","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1111\/all.70261","article-title":"Correspondence: First peanut (Arachis hypogaea) allergen oral immunotherapy product out of sale\u2014a major drawback for food allergy immunotherapy?","volume":"81","author":"Arasi","year":"2026","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2026.07.007_bib33","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1001\/jama.2019.1113","article-title":"Effect of epicutaneous immunotherapy vs placebo on reaction to peanut protein ingestion among children with peanut allergy: the PEPITES randomized clinical trial","volume":"321","author":"Fleischer","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.jaci.2026.07.007_bib34","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.jaci.2020.06.028","article-title":"Long-term, open-label extension study of the efficacy and safety of epicutaneous immunotherapy for peanut allergy in children: PEOPLE 3-year results","volume":"146","author":"Fleischer","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.07.007_bib35","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jaci.2023.08.032","article-title":"Desensitization and remission after peanut sublingual immunotherapy in 1- to 4-year-old peanut-allergic children: a randomized, placebo-controlled trial","volume":"153","author":"Kim","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.07.007_bib36","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1111\/all.70111","article-title":"Peanut component-specific IgE and IgG4 are modulated by sublingual immunotherapy and are associated with remission in 1-4-year-old children","volume":"81","author":"Singh","year":"2026","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2026.07.007_bib37","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1056\/NEJMoa1414850","article-title":"Randomized trial of peanut consumption in infants at risk for peanut allergy","volume":"372","author":"Du Toit","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2026.07.007_bib38","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1111\/all.16451","article-title":"Allergen-specific IgE is a stronger predictor of remission following peanut oral immunotherapy than age in children aged 1-10 years","volume":"80","author":"Ashley","year":"2025","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2026.07.007_bib39","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1111\/all.15749","article-title":"An update on recent developments and highlights in food allergy","volume":"78","author":"Locke","year":"2023","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2026.07.007_bib40","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/cea.13824","article-title":"Mechanisms of oral immunotherapy","volume":"51","author":"Barshow","year":"2021","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaci.2026.07.007_bib41","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.jaci.2017.12.979","article-title":"Immune mechanisms of oral immunotherapy","volume":"141","author":"Kulis","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.07.007_bib42","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.jaci.2019.10.038","article-title":"Sustained successful peanut oral immunotherapy associated with low basophil activation and peanut-specific IgE","volume":"145","author":"Tsai","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.07.007_bib43","doi-asserted-by":"crossref","first-page":"6646","DOI":"10.1038\/s41467-022-34222-8","article-title":"CD8+ T cell differentiation status correlates with the feasibility of sustained unresponsiveness following oral immunotherapy","volume":"13","author":"Kaushik","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.jaci.2026.07.007_bib44","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1016\/j.jaci.2022.05.020","article-title":"Kinetics of basophil hyporesponsiveness during short-course peanut oral immunotherapy","volume":"150","author":"Kulis","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.07.007_bib45","doi-asserted-by":"crossref","DOI":"10.1172\/JCI150634","article-title":"Peanut oral immunotherapy differentially suppresses clonally distinct subsets of T helper cells","volume":"132","author":"Monian","year":"2022","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaci.2026.07.007_bib46","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/j.jaci.2021.09.029","article-title":"Allergen-specific T cells and clinical features of food allergy: lessons from CoFAR immunotherapy cohorts","volume":"149","author":"Berin","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.07.007_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2020.108568","article-title":"Transcriptional changes in peanut-specific CD4+ T cells over the course of oral immunotherapy","volume":"219","author":"Wang","year":"2020","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jaci.2026.07.007_bib48","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/all.14639","article-title":"Roles of follicular helper and regulatory T cells in allergic diseases and allergen immunotherapy","volume":"76","author":"Yao","year":"2021","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2026.07.007_bib49","doi-asserted-by":"crossref","DOI":"10.1172\/JCI164501","article-title":"Immunotherapy-induced neutralizing antibodies disrupt allergen binding and sustain allergen tolerance in peanut allergy","volume":"133","author":"LaHood","year":"2023","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaci.2026.07.007_bib50","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1016\/j.jaci.2024.02.017","article-title":"Neutralizing IgG4 antibodies are a biomarker of sustained efficacy after peanut oral immunotherapy","volume":"153","author":"Keswani","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.07.007_bib51","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/pai.12535","article-title":"Differential response in allergen-specific IgE, IgGs, and IgA levels for predicting outcome of oral immunotherapy","volume":"27","author":"Sugimoto","year":"2016","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.jaci.2026.07.007_bib52","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.jaci.2014.05.042","article-title":"Oral immunotherapy induces IgG antibodies that act through Fc\u03b3RIIb to suppress IgE-mediated hypersensitivity","volume":"134","author":"Burton","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.07.007_bib53","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1056\/NEJMoa2312382","article-title":"Omalizumab for the treatment of multiple food allergies","volume":"390","author":"Wood","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2026.07.007_bib54","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jaci.2020.08.039","article-title":"Determinants of omalizumab dose-related efficacy in oral immunotherapy: evidence from a cohort of 181 patients","volume":"147","author":"Azzano","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.07.007_bib55","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41467-019-13815-w","article-title":"The mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from omalizumab","volume":"11","author":"Gasser","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.jaci.2026.07.007_bib56","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.intimp.2010.02.001","article-title":"Accumulated immune complexes of IgE and omalizumab trap allergens in an in vitro model","volume":"10","author":"Hsu","year":"2010","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.jaci.2026.07.007_bib57","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1111\/all.15567","article-title":"Ligelizumab impairs IgE-binding to plasmacytoid dendritic cells more potently than omalizumab and restores IFN-\u03b1 production and FOXP3+ Treg generation","volume":"78","author":"Benito-Villalvilla","year":"2023","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2026.07.007_bib58","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.jaci.2019.07.045","article-title":"CD23 provides a noninflammatory pathway for IgE-allergen complexes","volume":"145","author":"Engeroff","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.07.007_bib59","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.jaci.2025.05.014","article-title":"Introduction of allergenic foods after treatment with omalizumab","volume":"156","author":"Dantzer","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.07.007_bib60","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.jaci.2015.10.005","article-title":"A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow\u2019s milk allergy","volume":"137","author":"Wood","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.07.007_bib61","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1056\/NEJMoa1314768","article-title":"Dupilumab treatment in adults with moderate-to-severe atopic dermatitis","volume":"371","author":"Beck","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2026.07.007_bib62","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/all.16404","article-title":"Efficacy and safety of dupilumab in children with peanut allergy: a multicenter, open-label, phase II study","volume":"80","author":"Sindher","year":"2025","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2026.07.007_bib63","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.jaci.2013.04.056","article-title":"Omalizumab increases the intrinsic sensitivity of human basophils to IgE-mediated stimulation","volume":"132","author":"Macglashan","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.07.007_bib64","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1111\/all.16420","article-title":"Dupilumab as an adjunct to oral immunotherapy in pediatric patients with peanut allergy","volume":"80","author":"Chinthrajah","year":"2025","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2026.07.007_bib65","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.jaci.2022.08.026","article-title":"Attenuating the atopic march: meta-analysis of the dupilumab atopic dermatitis database for incident allergic events","volume":"151","author":"Geba","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.07.007_bib66","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1111\/all.16129","article-title":"Immunotherapy and biologics in the management of IgE-mediated food allergy: systematic review and meta-analyses of efficacy and safety","volume":"79","author":"Riggioni","year":"2024","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2026.07.007_bib68","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1111\/cea.14304","article-title":"Outcomes reported in randomized controlled trials for mixed and non\u2013IgE-mediated food allergy: systematic review","volume":"53","author":"Bel Imam","year":"2023","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaci.2026.07.007_bib69","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.anai.2014.06.027","article-title":"Food allergy quality of life","volume":"113","author":"Greenhawt","year":"2014","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2026.07.007_bib70","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1097\/ACI.0000000000000271","article-title":"Food allergy quality of life and living with food allergy","volume":"16","author":"Greenhawt","year":"2016","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.07.007_bib71","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.jaip.2015.07.023","article-title":"Differences in caregiver food allergy quality of life between tertiary care, specialty clinic, and caregiver-reported food allergic populations","volume":"4","author":"Ward","year":"2016","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2026.07.007_bib72","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.anai.2014.12.022","article-title":"Treatment of allergic reactions and quality of life among caregivers of food-allergic children","volume":"114","author":"Ward","year":"2015","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2026.07.007_bib73","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.anai.2017.09.060","article-title":"Preliminary psychometric analyses and clinical performance of a caregiver self-efficacy scale for food allergy self-management","volume":"120","author":"Greenhawt","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2026.07.007_bib74","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.anai.2019.05.015","article-title":"Providing cost-effective care for food allergy","volume":"123","author":"Shaker","year":"2019","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2026.07.007_bib75","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.anai.2019.05.012","article-title":"A primer on cost-effectiveness in the allergy clinic","volume":"123","author":"Shaker","year":"2019","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2026.07.007_bib76","doi-asserted-by":"crossref","first-page":"4200","DOI":"10.1016\/j.jaip.2021.10.006","article-title":"A practical guide to understanding cost-effectiveness analyses","volume":"9","author":"Greenhawt","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2026.07.007_bib77","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1056\/NEJMoa1812856","article-title":"Oral immunotherapy for peanut allergy [abstract AR101]","volume":"379","author":"Vickery","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2026.07.007_bib78","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/j.jaip.2020.12.029","article-title":"Continuous and daily oral immunotherapy for peanut allergy: results from a 2-year open-label follow-on study","volume":"9","author":"Vickery","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2026.07.007_bib79","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/S2352-4642(20)30234-0","article-title":"Efficacy and safety of oral immunotherapy with AR101 in European children with a peanut allergy (ARTEMIS): a multicentre, double-blind, randomised, placebo-controlled phase 3 trial","volume":"4","author":"Hourihane","year":"2020","journal-title":"Lancet Child Adolesc Health"},{"key":"10.1016\/j.jaci.2026.07.007_bib80","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jaip.2020.08.015","article-title":"Improvements in quality of life in children following epicutaneous immunotherapy (EPIT) for peanut allergy in the PEPITES and PEOPLE studies","volume":"9","author":"DunnGalvin","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2026.07.007_bib81","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1111\/all.15323","article-title":"Psychometric parameters of food allergy quality of life during an allergen immunotherapy trial","volume":"77","author":"Lins de Holanda Coelho","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2026.07.007_bib82","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1111\/all.70046","article-title":"Systematic review and meta-analysis of oral immunotherapy effect on food allergy-related quality of life","volume":"80","author":"Rosser","year":"2025","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2026.07.007_bib83","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1016\/j.jaci.2017.01.030","article-title":"Peanut allergen threshold study (PATS): novel single-dose oral food challenge study to validate eliciting doses in children with peanut allergy","volume":"139","author":"Hourihane","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.07.007_bib84","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.anai.2024.07.034","article-title":"Food allergy yardstick: where does omalizumab fit?","volume":"134","author":"Anagnostou","year":"2025","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2026.07.007_bib85","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.3242","article-title":"Estimation of health and economic benefits of commercial peanut immunotherapy products: a cost-effectiveness analysis","volume":"2","author":"Shaker","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jaci.2026.07.007_bib86","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1001\/jama.2016.21040","article-title":"Effect of 2 years of treatment with sublingual grass pollen immunotherapy on nasal response to allergen challenge at 3 years among patients with moderate to severe seasonal allergic rhinitis: the GRASS randomized clinical trial","volume":"317","author":"Scadding","year":"2017","journal-title":"JAMA"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674926005233?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674926005233?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T09:59:13Z","timestamp":1791194353000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674926005233"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":84,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0091674926005233"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2026.07.007","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"International perspective on obtaining disease modification with food allergy therapies","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2026.07.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}